Genmab — Februar 2019
-
Vi skal ikke glemme, at vi har været igennem et langt generelt euforisk bullrace siden 2010. I 2017 fik pharma og biotek et skud for boven. Den fangede analytikerne eller os her i chatten ikke rigtigt
alvoren af. -
Helge: Der er så bare ikke så mange optimister, der giver udtryk for at de er det pt. Og der er ellers ikke meget forkert i det du skriver ! Jeg tror rigtig mange er holdt op med at lytte til analytikerne......der er jo vådeskud i massevis. Det er nok en god ide, at der mange der er bleven lang i Genmab ! For en god ordens skyld , så beholder jeg mine lige indtil jeg kan gøre en fantastisk handel, og det tror jeg, at jeg kommer til.....og en god handel er minimum kurs 2000.........
-
Den gang troede jeg at den røg i kurs 5.
-
Det gjorde den så ikke.
-
Var ude dengang ...Købte først i 68.
-
-
Mit indlæg var nu ikke myntet på nogen bestemt, men kun nogle generelle betragtninger. Selvfølgelig mener du det du skriver..... det skal vi da også som udgangspunkt :-). Iøvrigt er jeg enig med dig omkring kursudvikling... jeg tror og håber du får ret. Heldigvis er der da fortsat optimister herinde....dem kan vi ikke undvære.
-
Er det den publicering vi venter på for TV ? Har dog ikke set den i Lancet Oncology endnu https://www.hippocraticpost.com/cancer/brand-new-drug-kills-cancer-cells-from-within/
-
Nå den er væk igen - men På Google ser man denne tekst: "for 3 timer siden - The innovative new drug, called tisotumab vedotin (or TV for short), releases a toxic substance to kill cancer cells from within. The results have been so positive the drug has now moved forward to phase II trials in cervical cancer and will be"
-
64 stillingsopslag https://genmab.loop.jobs/jobs
-
he study was published in The Lancet Oncology and funded by Genmab and Seattle Genetics.
The researchers found that a significant minority of cancer patients responded to the drug, with their tumours either shrinking or stopping growing.
They saw responses in 27 per cent of patients with bladder cancer, 26.5 per cent with cervical cancer, 14 per cent ovarian cancer, 13 per cent with oesophageal, 13 per cent with non-small cell lung and 7 per cent with endometrial cancer -
Responses lasted an average of 5.7 months, and up to 9.5 months in some patients.
The main side effects reported from the study were nose bleeds, fatigue, nausea and eye problems – but halfway through the trial the researchers adjusted the protocol to reduce these eye-related effects.
TV is made up of a toxic drug attached to the tail end of an antibody. The antibody is designed to seek out a receptor called ‘tissue factor’ – -
present at high levels on the surface of many cancers cells and linked with worse survival. Binding to tissue factor draws the drug inside cancer cells, where it can kill them from within.
The trial initially recruited 27 patients to assess safety and establish the right dose, before expanding to a further 120 patients primarily to look at whether the drug was hitting the right target but also at what effect it had on tumours. -
The majority of patients in the early trial had advanced stage cancer (spread locally or around the body) that had already been treated with, and became resistant to, an average of three different types of treatment.
TV is now being trialled in other cancer types including bowel, pancreatic, squamous cell lung and head and neck, as well as in a phase II trial as a second-line treatment for cervical cancer.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind